GlassScriptPhysician profile
Kenneth Frank Guarnieri
NPI 1679547830
$28,247.14
in general payments reported to CMS, 2019-2025
58 companies · $4,543 in 2025
The $4,543 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,645 · 2020: $3,043 · 2021: $4,341 · 2022: $4,690 · 2023: $5,056 · 2024: $3,931 · 2025: $4,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,509.12 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,860.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,665.99 | 2021-2025 | |
| Pfizer INC. | $2,123.53 | 2019-2025 | |
| Lilly USA, LLC | $2,066.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,864.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,637.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,423.64 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $999.28 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $853.10 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $824.89 | 2022-2025 | |
| Amarin Pharma, INC. | $671.67 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $670.14 | 2019-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $664.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $663.76 | 2019-2025 | Spravato |
| Sumitomo Pharma America, INC. | $514.23 | 2023-2025 | Gemtesa, Myfembree |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $468.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $434.96 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $434.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $347.14 | 2020-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $342.38 | 2019-2022 | |
| Allergan, INC. | $316.91 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $297.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $281.59 | 2019-2021 | |
| Esperion Therapeutics, INC. | $250.85 | 2020-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $221.29 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $198.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $196.28 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $166.83 | 2020-2025 | Zoryve |
| Ardelyx, INC. | $143.27 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $141.86 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Inspire Medical Systems, INC. | $141.19 | 2024-2025 | Inspire |
| Antares Pharma, INC. | $132.39 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Mylan Specialty L.P. | $127.40 | 2021-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $118.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.74 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $95.02 | 2022-2023 | Quviviq |
| Lexicon Pharmaceuticals, INC. | $66.90 | 2023 | Inpefa |
| Medtronic, INC. | $63.82 | 2023-2025 | Intellis Adaptivestim, Venaseal |
| Redhill Biopharma INC. | $61.44 | 2020-2021 | |
| Sanofi Pasteur INC. | $55.46 | 2019-2020 | |
| Scpharmaceuticals INC. | $50.34 | 2025 | |
| Scilex Pharmaceuticals INC. | $50.21 | 2019 | |
| Bardy Diagnostics, INC. | $40.00 | 2020 | |
| Paratek Pharmaceuticals, INC. | $37.10 | 2024 | Nuzyra |
| Verona Pharma, INC. | $36.98 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $35.66 | 2024 | Watchman Access System, Watchman Flx |
| Genentech USA, INC. | $31.45 | 2020 | |
| Almatica Pharma LLC | $28.01 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.00 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $25.31 | 2023 | Rexulti |
| Madrigal Pharmaceuticals | $24.23 | 2025 | Rezdiffra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.75 | 2025 | Caplyta |
| Kiniksa Pharmaceuticals, LTD. | $23.39 | 2021 | |
| Eisai INC. | $23.10 | 2021 | |
| Recordati_rare_diseases_inc. | $22.54 | 2025 | Isturisa |
| Regeneron Healthcare Solutions, INC. | $20.27 | 2019 | |
| Urovant Sciences INC | $19.47 | 2022 | |
| Altathera Pharmaceuticals LLC | $13.01 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Guarnieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.